Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma
Recruiting · Phase 1, Phase 2 · NCT06029309
Conditions: Mantle Cell Lymphoma
At a glance
- Research payments reported, 2025
- $58,344
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 27
About the trial
- Sponsor
- Alvaro Alencar, MD (with Incyte Corporation, BeOne Medicines)
- Tested
- Zanubrutinib (drug), Tafasitamab (drug)
- Dates
- Started 2024-05-03; completion 2032-05-01
- Results posted
- Not yet
The main purpose of this study to find the ideal dose for the combination treatment of Zanubrutinib and Tafasitamab in patients with mantle cell lymphoma. Another purpose is to assess how well the combination treatment works in patients with the study disease.
From ClinicalTrials.gov, last updated 2026-09-21. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beigene USA, Inc. reported $58,344 in research payments for this study in 2025 (1 payments).
Products named: Brukinsa
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Miami $58,344
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.